The Malignant Melanoma Program at Wake Forest Baptist Health employs a multidisciplinary approach for the management of patients with all stages of this disease. The goals of the program are centered on unequivocal excellence in all areas of care for patients with malignant melanoma.
Measurable patient characteristics that predict better tolerance have not been widely studied and are desperately needed in clinical practice to inform treatment decision-making and individualize care for each older adult with AML.
Alterations in the chromosomes of two genes have been implicated in an increased risk of prostate cancer mortality, and the discovery holds promise for distinguishing which patients are candidates for more aggressive therapy.
Perry Shen, MD, FACS, and Clancy Clark, MD, from Wake Forest Baptist Health Comprehensive Cancer Center, discuss advances in the management of hepatic and pancreatic malignancies.